Skip to main content
. 2022 Aug 12;13:939311. doi: 10.3389/fimmu.2022.939311

Figure 1.

Figure 1

Study processes for the two participant cohorts. Eligible participants were enrolled to receive two doses of CoronaVac on day 0 and day 28 (Cohort 1). After phase 1 recruitment, participants completed the two-dose immunization with Covilo were recruited (Cohort 2). Blood samples were collected and tested at Day 0, Day 28, Day 56 and Day 210 for Cohort 1 participants, while at Day 56 and Day 210 for Cohort 2 participants.